Press Releases

September 21, 2022
Paper describes key insight into integrin conformation, overcoming critical drug development challenge Company lauds Tim Springer, PhD, scientific founder of Morphic and Fu-Yang “Albert” Lin, PhD, first company employee WALTHAM, Mass., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq:
June 9, 2022
WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Bruce Rogers, Ph.D., President of Morphic, will give a
Displaying 1 - 10 of 16
Scroll to Top